Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in ...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Perhaps most reassuring about semaglutide’s cardiovascular benefits is their durability over time. The protection against major adverse cardiac events persisted throughout the study’s follow ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

Semaglutide’s cardiovascular benefits remain effective in individuals with impaired kidney function, offering heart protection even with reduced renal health.

However, the new Lancet study found semaglutide had similar benefits in people with heart failure: the drug was linked to a 28% reduction in major adverse cardiovascular events, and a 24% ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

Citation: Semaglutide's cardiovascular benefits are maintained in people with impaired kidney function, research finds (2024, September 11) retrieved 16 May 2025 from https://medicalxpress.com ...